Paper38947372
Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.
Gómez-Gaviria M and 3 others. Infect Drug Resist, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses. Papers, record 38947372. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38947372
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References127
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33821795 | Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. | Elife | 2021 | https://conductscience.org/library/papers/33821795 | PubMed |
| 2 | 34152816 | In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34152816 | PubMed |
| 3 | 28685162 | In Vivo Indicators of Cytoplasmic, Vacuolar, and Extracellular pH Using pHluorin2 in Candida albicans. | mSphere | 2017 | https://conductscience.org/library/papers/28685162 | PubMed |
| 4 | 34368017 | Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/34368017 | PubMed |
| 5 | 19109335 | Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. | J Antimicrob Chemother | 2009 | https://conductscience.org/library/papers/19109335 | PubMed |
| 6 | 23931748 | Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. | Cell Metab | 2013 | https://conductscience.org/library/papers/23931748 | PubMed |
| 7 | 29653129 | Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. | Adv Drug Deliv Rev | 2018 | https://conductscience.org/library/papers/29653129 | PubMed |
| 8 | 33052959 | Identification of two potential inhibitors of Sporothrix brasiliensis and Sporothrix schenckii in the Pathogen Box collection. | PLoS One | 2020 | https://conductscience.org/library/papers/33052959 | PubMed |
| 9 | 25057459 | Drug repurposing and human parasitic protozoan diseases. | Int J Parasitol Drugs Drug Resist | 2014 | https://conductscience.org/library/papers/25057459 | PubMed |
| 10 | 8667037 | In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. | J Chemother | 1995 | https://conductscience.org/library/papers/8667037 | PubMed |
| 11 | 19538521 | HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces. | Mycoses | 2010 | https://conductscience.org/library/papers/19538521 | PubMed |
| 12 | 24197921 | Endemic mycoses in immunocompromised hosts. | Curr Infect Dis Rep | 2013 | https://conductscience.org/library/papers/24197921 | PubMed |
| 13 | 32942693 | Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/32942693 | PubMed |
| 14 | 10855824 | The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. | J S Afr Vet Assoc | 1999 | https://conductscience.org/library/papers/10855824 | PubMed |
| 15 | 28702025 | Cellular and Molecular Defects Underlying Invasive Fungal Infections-Revelations from Endemic Mycoses. | Front Immunol | 2017 | https://conductscience.org/library/papers/28702025 | PubMed |
| 16 | 20707818 | The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents. | FEMS Yeast Res | 2010 | https://conductscience.org/library/papers/20707818 | PubMed |
| 17 | 32253207 | In Vitro and In Vivo Study on the Synergistic Effect of Minocycline and Azoles against Pathogenic Fungi. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32253207 | PubMed |
| 18 | 23457073 | Interaction of miltefosine with the lipid and protein components of the erythrocyte membrane. | J Pharm Sci | 2013 | https://conductscience.org/library/papers/23457073 | PubMed |
| 19 | 15329361 | Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. | J Antimicrob Chemother | 2004 | https://conductscience.org/library/papers/15329361 | PubMed |
| 20 | 34071195 | Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches. | J Fungi (Basel) | 2021 | https://conductscience.org/library/papers/34071195 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42794569 | WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794569 | PubMed |
| 42384304 | Preventive action of ketamine alone and in combination with antifungals on Candida biofilm formation in catheters. | Int Microbiol | 2026 | https://conductscience.org/library/papers/42384304 | PubMed |
| 42353721 | Exploring the Antifungal, Antibiofilm, and Wound Healing In Vitro Properties of N-(4-Methoxycinnamoyl)-Anthranilic Acid as a Supportive Strategy for Ocular Fungal Infections. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42353721 | PubMed |
| 41375247 | Iodinated Near-Infrared Dyes as Effective Photosensitizers for the Photodynamic Eradication of Amphotericin B-Resistant Candida Pathogens. | Molecules | 2025 | https://conductscience.org/library/papers/41375247 | PubMed |
| 41162496 | Innovative green niosomal piperlongumine as a novel topical treatment for dermatophytosis in guinea pigs model. | Sci Rep | 2025 | https://conductscience.org/library/papers/41162496 | PubMed |
| 40670739 | In vivo efficacy of atorvastatin in the treatment of Tinea pedis: stepping forward into drug repositioning. | J Antibiot (Tokyo) | 2025 | https://conductscience.org/library/papers/40670739 | PubMed |
| 39728367 | New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions. | J Fungi (Basel) | 2024 | https://conductscience.org/library/papers/39728367 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38947372
GET https://conductscience.org/api/papers/v1/38947372/references?page=2